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Accuracy of the Delirium Observational
Screening Scale (DOS) as a screening tool
for delirium in patients with advanced
cancer
Elisabeth C. W. Neefjes1†, Maurice J. D. L. van der Vorst1,2†, Manon S. A. Boddaert3, Bea A. T. T. Verdegaal1,
Aart Beeker4, Saskia C. C. Teunissen5,6, Aartjan T. F. Beekman7, Wouter W. A. Zuurmond8,9, Johannes Berkhof10
and Henk M. W. Verheul11*
Abstract
Background: The Delirium Observation Screening Scale (DOS) was developed to facilitate early recognition of
delirium by nurses during routine clinical care. It has shown good validity in a variety of patient populations, but
has not yet been validated in hospitalized patients with advanced cancer, although the DOS is commonly used in
this setting in daily practice. The aim of this study was to evaluate the accuracy of the DOS in hospitalized patients
with advanced cancer using the revised version of the Delirium Rating Scale (DRS-R− 98) as the gold standard.
Methods: Patients with advanced cancer admitted to the medical oncology ward were screened for delirium with
the DOS and DRS-R−98. Sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) of
the DOS were calculated, using a DOS score ≥ 3 as a cut-off for delirium.
Results: Ninety-five DOS negative and 98 DOS positive patients were identified. Sensitivity of the DOS, was > 99.9%
(95%-CI, 95.8–100.0%), specificity was 99.5% (95%-CI 95.5–99.96%), PPV was 94.6% (95% CI 88.0–97.7), and NPV was
> 99.9% (95% CI 96.1–100.0).
Conclusions: The DOS is an accurate screening tool for delirium in patients with advanced cancer. Since it has the
benefit of being easily implicated in daily practice, we recommend to educate caregivers to screen patients with
advanced cancer by DOS analysis. By early recognition and adequate treatment of this distressing delirium
syndrome the quality of life of patients with advanced cancer can be improved.
Trial registration: ClinicalTrials.gov Identifier NCT01539733 (Feb 27, 2012 - retrospectively registered), Netherlands
Trial Register NTR2559 (Oct 7, 2010).
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Background
Delirium is the most common neuropsychiatric compli-
cation in patients with advanced cancer especially during
hospitalization, with incidence rates ranging from 16 to
85%, depending on the stage of disease [1–7]. In a previ-
ous study from our group we found a higher number of
patients with skin cancer and brain cancer in the group
of patients with delirium compared to the patients with-
out delirium [8]. Other studies showed conflicting re-
sults [9, 10]. Therefore, there is no compelling evidence
that delirium is more prevalent in certain cancer types.
Because attention and awareness deficits impede the
ability to communicate and participate in treatment
decisions and symptom assessment, delirium has a nega-
tive influence on quality of life in a crucial phase at the
* Correspondence: h.verheul@vumc.nl
†Elisabeth C. W. Neefjes and Maurice J. D. L. van der Vorst contributed
equally to this work.
11Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam
UMC, Vrije Universiteit, De Boelelaan 1117, Rm 3A46, Amsterdam 1081, HV,
the Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Neefjes et al. BMC Cancer          (2019) 19:160 
https://doi.org/10.1186/s12885-019-5351-8
end of life [1]. The presentation of delirium is quite
variable among patients, and even within a given patient
because of its waxing and waning course [11]. This ham-
pers recognition and adequate treatment of delirium [1].
Therefore it is recommended to screen for delirium in
patients with (advanced) cancer admitted to the hospital
[1, 11]. The diagnosis delirium should be made accord-
ing to the DSM-criteria for delirium. Currently, version
5 is the most recent, but most screening and diagnostic
instruments are based on the DSM-IV [12]. Efforts are
being made to validate these instruments with the DSM
5 criteria [13, 14].
Available screening instruments which have been de-
signed to be used by health care professionals for evalu-
ating patients for possible delirium symptoms include:
CAM [15], NEECHAM Confusion Scale [16], DOSS/
DOS [17, 18], Nu-DESC [5], ICDSC [19], and PAED
scale [20]. Some of these instruments have been de-
signed to be used in a specific treatment setting like the
ICU, whereas others focus on specific age groups, like
children and adolescents. There is no specific screening
instrument for delirium in patients with advanced can-
cer. A comparison between various features of the avail-
able screening and diagnostic instruments for delirium
in adults was made by Grover and Kate in 2012 [12].
Delirium screening should be preferably performed by
nurses because they have frequent contact with the pa-
tient throughout the day, and could therefore easily ob-
serve changes in the patient’s attention and awareness
over time, which is one of the main criteria for delirium
according to the DSM 5 criteria [21]. The Delirium Ob-
servation Scale (DOS) appears to be the most suitable
nurse-rated screening instrument for patients in general
medical and surgical wards with a strong foundation in
the DSM-IV criteria and good psychometric properties
[3, 22]. It can be assessed by nurses without specific
training, and is experienced as user-friendly. A previous,
small study by Detroyer et al suggests good sensitivity
and specificity of the DOS in a palliative care population
[23]. The aim of our study is to evaluate the diagnostic
accuracy of the DOS as screening instrument for hospi-
talized patients diagnosed with advanced cancer.
Methods
Patients
Hospitalized patients with advanced cancer admitted to
the medical oncology ward of six sites (1 university
cancer center, 3 teaching hospitals, 2 high-care hospices)
in the Netherlands were recruited between January 2011
through December 2015. Patients and/or their legal rep-
resentatives were asked for informed consent to partici-
pate in this diagnostic study, as part of a randomized
controlled trial (RCT), which compared the efficacy of halo-
peridol to olanzapine in case the patient was diagnosed
with delirium (ClinicalTrials.gov identifier NCT01539733).
The study was conducted according to Good Clinical
Practice guidelines, the Declaration of Helsinki and local
laws, and was approved by the institutional review boards
of each participating study site.
Patients with any type of cancer in an advanced stage,
of 18 years and older who were fluent in the Dutch
language were considered eligible. Patients with pre-
existing cognitive impairment (such as Alzheimer’s
disease), or psychiatric comorbidity that might hamper
delirium diagnosis (e.g. schizophrenia) were excluded
from this study. Also, patients using antipsychotic or
neuroleptic medication for other reasons than neuro-
pathic pain management were excluded. Additional ex-
clusion criteria were based on contra-indications for the
use of haloperidol or olanzapine, like high risk at alcohol
withdrawal delirium, glaucoma, Parkinson’s disease,
QTc-interval prolongation > 500 msec at baseline ECG, a
history of malignant neuroleptic syndrome and con-
comitant treatment with anti-convulsive drugs.
Study assessments
Patients who were included in the trial were screened
for delirium by their nurse using the DOS at the mo-
ment of admittance, and subsequently three times a day,
biweekly during their stay in the hospital. Each DOS
positive patient (DOS ≥3) was randomly matched with a
DOS negative patient (DOS < 3) to evaluate the accuracy
of the DOS. DOS positive patients and the randomly
matched DOS negative patients were assessed with the
Delirium Rating Scale-R− 98 (DRS-R-98) by a trained
independent assessor, who was blinded with regard to
the DOS score of a patient.
To prevent duplication bias patients were excluded
from the DOS negative group if they were included in
the randomised treatment part of the study during a
later admission.
DOS
The original version, the Delirium Observational
Screening Scale (DOSS), consisted of a 25-item scale
based on the DSM-IV criteria for delirium [17]. The
scale was designed to capture early symptoms of
delirium that nurses could observe during regular
care. The scale was subsequently reduced to 13 obser-
vations, and is known as the Delirium Observation
Scale (DOS) [18]. Each item can be rated as normal
(score, 0) or abnormal (score, 1). A total score of 3
or more points indicates delirium. Completion of the
instrument requires less than 5 min. A small descrip-
tive study evaluated the DOS in patients admitted to
a palliative care unit [23]. The DOS was compared to
the CAM and the Delirium Index and showed good
psychometric properties. Moreover, it was experienced
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as user-friendly by the bedside nurses. Internal consistency,
predictive validity, and concurrent and construct validity
of the DOS were tested in two prospective studies in high
risk groups: geriatric medicine patients and elderly hip
fracture patients [18]. The DOS has high internal
consistency (0.96) and high content validity (α = 0.93). In
these study groups the DOS scale had a sensitivity of
89–100% and a specificity of 68–88%. The positive pre-
dictive value was 47%, the negative predictive value was
almost 100%. The DOS was also able to measure sever-
ity of delirium in geriatric patients [24]. Moreover, the
DOS proved to be a good instrument to facilitate early
recognition of delirium in patients who undergo cardiac
surgery: the sensitivity and specificity of the DOS was
100 and 96.6% respectively [25].
DRS-R-98
The DRS-R-98 is a revised version of the Delirium Rat-
ing Scale [26, 27]. The DRS-R-98 consists of 13 severity
items that are scored from 0 (not present) to 3 points
(severely present), and three diagnostic items, all of
which are rated over the past 24 h. Severity scores range
from 0 to 39, and total scores range from 0 to 46. The
DRS-R-98 is designed to be completed by a trained pro-
fessional and takes about 10 to 15min to complete [27].
The DRS-R-98 has a high internal consistency (0.90) and
when using a cut-off of 17.75 points on the total scale a
sensitivity of 92% and specificity of 95% [27].
Inter-rater-consistency was high in the validation study
by Trzepacz et al (0.99) [27]. The DRS-R-98 severity
scale has the great benefit that it can be used for
Fig. 1 Study flow chart
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repeated measurements to assess the response to delir-
ium treatment [27]. Recently, the DRS-R-98 has been
validated for the new DSM-5 criteria [28]. The
DRS-R-98 was chosen as a gold standard to evaluate the
accuracy of the DOS because of its good psychometric
qualities, because it has been validated in a palliative
care setting, and is available in the Dutch language (the
first language of the included patients and the re-
searchers in this study group) [27].
Statistics
A sample size calculation was conducted to determine an
80% power in demonstrating that the DOS has a sensitiv-
ity of at least 90%. A sample of 100 patients per group
(DOS positive vs. DOS negative) was needed when the
sensitivity of the DOS was assumed to be 95% [18, 25].
Primary endpoints to assess the accuracy of the DOS
are the sensitivity and specificity of the DOS score
compared with the DRS-R-98 as the gold standard. Sen-
sitivity, specificity, negative and positive predictive value
are reported with 95% confidence intervals, calculated
with the Wilson method [29]. Analyses will be corrected
for partial verification, because only a proportion of
DOS negative patients admitted to the study sites were
included in this study. For the baseline characteristics
standard descriptive statistics were used. Statistical ana-
lyses were performed with IBM SPSS version 22.0 (IBM,
Armonk, NY, USA).
Results
Between January 2010 and January 2016, 100 consecu-
tive DOS negative and 95 DOS positive patients were
included in the study. One DOS positive patient with-
drew consent for participating in the study while recov-
ering from delirium. Four DOS negative patients were
included in the DOS positive group during a later
hospital admission. These patients were excluded from
the DOS negative group during the analyses. For one
patient in each group all data were missing, leading to a
total of 94 DOS negative and 93 DOS positive patients
(Fig. 1). The demographic and clinical characteristics
are described in Table 1. The mean (SD) age was 68
(11) in the DOS positive group and 60 (13) in the DOS
negative group (p < 0.001). Other characteristics ob-
tained at baseline were not significantly different
between the groups. None of the patients in the DOS
negative group were diagnosed with delirium.
Eighty-eight of the patients in the DOS positive group
were diagnosed with delirium, see Table 2. The sensitiv-
ity and specificity of the DOS were > 99.9% (95%CI:
95.8–100.0%) and 99.6.% (95%CI: 95.5–100.0%) respect-
ively, the negative predictive value (NPV) was 94.6
(95%CI, 88.0–97.7%), and the positive predictive value
(PPV) was > 99.9% (95%CI, 96.1–100.0%), see Table 3.
The median DOS score of the DOS positive patients
was 4.0 (IQR 4.0–6.0). Higher DOS scores correlated
with higher DRS-R-98 total scores, see Table 4.
Four of the five patients with a DOS of 3 or higher
who were not confirmed to be delirious by the
DRS-R-98 score (score < 17.75), had DRS-R-98 total
scores > 12 points. The latter cut-off has been used as a
more inclusive cut-off for delirium in some studies
[30, 31]. One patient scored being delirious on the
DOS but only scored three points on the DRS-R-98.
We speculate that he/she may have displayed only
temporarily signs of delirium which had resolved by
the time the DRS-R-98 was conducted.
Table 1 Baseline characteristics
DOS negative
N = 94 (SD or %)
DOS positive
N = 93 (SD or %)
p
Age 60 (12.9) 68 (11.1) <.001
Gender
Male 58 (62%) 66 (71%)
Female 36 (38%) 27 (29%) .180
Tumor type
Gastro-intestinal 40 (43%) 28 (30%)
Breast 6 (6%) 6 (7%)
Genito-urethral 23 (25%) 29 (32%)
Skin 4 (4%) 8 (9%)
Lung 0 3 (3%)
Head&neck 5 (5%) 2 (2%)
Brain 0 2 (2%)
Sarcoma 4 (4%) 1 (1%)
Hematological 1 (1%) 9 (10%)
Other 11 (12%) 5 (5%) .484
Brain metastasis
No 89 (95%) 87 (94%)
Yes 5 (5%) 6 (6%) .767
Baseline characteristics of the patients in this study. No statistically significant
differences were found except for age; Delirium Observational Scale (DOS)
positive patients, who screened positive for delirium with a score ≥ 3 on this
scale, tended to be older than DOS negative patients
Table 2 DOS vs. DRS-R-98
DRS-R-98 no
delirium (< 17.75)
DRS-R-98 delirium
(≥17.75)
Total
DOS no delirium (< 3) 94 0 94
DOS delirium (≥3) 5 88 93
Total 99 88
Distribution of the results of the DOS and DRS-R-98 scores
Neefjes et al. BMC Cancer          (2019) 19:160 Page 4 of 7
Discussion
To our knowledge this is the first study to evaluate the
accuracy of the DOS in a large group of patients with
advanced cancer. Our data showed that the DOS is a
very sensitive and specific instrument to screen for delir-
ium in hospitalized patients with advanced cancer. It
might also give an impression of the delirium severity.
Compared to other screening instruments, such as the
CAM [15], NEECHAM Confusion Scale [16], and the
Nu-DESC [5], the DOS has shown better sensitivity and
specificity. It has the benefits that it is quick to adminis-
ter, and does not require training [12].
Strengths of the study are that we were able to include
a large group of patients, and that the DRS-R-98 assess-
ment was performed by an independent assessor who
was blinded to the DOS score of the patient. Also, the
nursing staff was already used to complete the DOS
scale during routine care, so we did not need a run-in or
training period for the study. In addition, during the
conduct of the study the nurses gave very positive spon-
taneous feedback on the effort it took to complete this
questionnaire.
There are several limitations to this study. First, the
observed incidence of delirium at the study sites was low
[8]. Therefore, it was necessary to adjust the results for
non-verification. Even after this adjustment, we have
convincing results that the DOS is an accurate screening
instrument for delirium screening in patients with ad-
vanced cancer. Second, while other baseline characteris-
tics were evenly distributed over the DOS positive and
DOS negative patients, patients who were DOS negative
were younger than the DOS positive patients. This is
concordant with the fact that advanced age is one of the
known risk factors for the development of delirium [2].
Using age-matched comparators would however hamper
the applicability of this study to the whole population of
hospitalized patients with advanced cancer.
For this study we used a DRS-R-98 score of > 17.75 as
a cut-off for delirium. The patients who screened posi-
tive for delirium with the DOS scale but not with the
DRS-R-98, had (except for one) DRS-R-98 scores > 12,
which has been classified as subsyndromal delirium in
previous studies [30, 31]. One might argue that it might
be beneficial for these patients as well to be treated for
their symptoms.
Conclusions
The DOS is an accurate instrument for detection of de-
lirium in a population of hospitalized patients with ad-
vanced cancer. The DOS can be completed by nurses
based on the observations made during regular nursing
care, which makes it easily applicable as a screening tool
for delirium in patients with advanced cancer. By early
recognition and adequate treatment of this distressing
delirium syndrome the quality of life of patients with ad-
vanced cancer can be improved.
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